Veltis® Engineered Albumin Platform Technology
Sartorius proprietary drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your API.
Related Products and Services
Supporting Your Value Proposition With Veltis®
Adopting the albumin-enabling solution, Veltis® can support the development of effective, patient-friendly treatments and optimize their potential success in the market through a value proposition that is attractive to regulators, payers, clinicians, and patients.
Reach out to us for more information on how our Veltis® technology platform could elevate your treatment's potential.
Interact with the diagram to understand the application potential of Veltis® and how it can support your program:
Optimise Drug Half-Life With Veltis®
Biopharmaceuticals offer several advantages over conventional pharmaceuticals. However, many promising biopharmaceuticals, such as protein and peptides drug candidates fail to produce the desired clinical effect because of rapid inactivation, removal from the body and/or inadequate delivery at site of action. These shortcomings of biologics often result in the requirement for both high and more frequent dosing, with the consequent risk of side effects and reduced treatment compliance.
Our Veltis® technology platform is developed to address these key challenges by leveraging – the human body’s own delivery system. Considered the natural carrier for distribution of pharmaceuticals around the human body, albumin is inherently designed to engage with a range of chemical and biological compounds.
Enhance your API's half-life with Veltis®. Connect with our team to learn how.
Leverage Veltis® to Deliver APIs
Random biodistribution and a lack of specificity to the diseased tissue that is the desired target of an API often demands higher dosing, which naturally means introducing the risk of side effects. Albumin has an innate ability to concentrate in specific diseased tissue, and, therefore, may help you to target specific tissues, and in [certain instances] tumors, with your API.
Serum albumin has been shown to accumulate in tumors that have increased FcRn expression. Veltis® offers an engineered albumin solution with enhanced targeting capabilities for developers looking for a consistent, serum-free albumin alternate for conjugations that aide API concentration in tumors.
Following similar mechanisms as the targeting ability of albumin against tumours, site specific targeting by albumin against inflamed tissue has been demonstrated using a collagen induced arthritis model.
Connect with our team to understand how Veltis® could support you to deliver increased targeting specificity to the benefit of your biopharmaceutical.
Create Bispecific Therapies
Veltis® increases payload capacity and delivers an extended half-life, whilst also offering a consistent platform that supports dependable processes and outputs.
By combining site-specific conjugation to one or more thiols, with N and/or C-terminal fusion to albumin, it is possible to design a multitude of albumin drug constructs. The optimized albumin scaffold provided by Veltis® can support your project to develop bispecific biopharmaceuticals that deliver enhanced performance.
Consult our experts to understand how Veltis® could support your bi-specific biopharmaceutical development ambitions.
